Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Rhea-AI Summary
Apyx Medical (NASDAQ: APYX) reported a retrospective 113‑patient study of liposuction with and without Renuvion. Adding Renuvion showed higher Body‑Q satisfaction with excess skin (87.8 vs. 73.8) and abdominal appearance (68.8 vs. 45.0), over 50% lower abdominoplasty rates (30.0% vs. 67.1%), lower revision rates (12.0% vs. 37.5%), and similar complication rates (2.5% vs. 2.7%) versus power‑assisted liposuction alone over more than 12 months of follow‑up.
Positive
- Renuvion group showed higher Body‑Q excess skin satisfaction score (87.8 vs. 73.8; p=0.03)
- Higher abdominal appearance satisfaction without abdominoplasty (68.8 vs. 45.0; p=0.039)
- Abdominoplasty rate more than 50% lower with Renuvion (30.0% vs. 67.1%)
- Revision rates lower in Renuvion cohort (12.0% vs. 37.5%; p=0.038)
- Complication rates similar between Renuvion and control groups (2.5% vs. 2.7%)
- Study adds to over 90 clinical documents supporting Renuvion and J‑Plasma
Negative
- Evidence comes from a 113‑patient, single‑surgeon retrospective study
- Outcomes limited to liposuction patients with more than 12‑month follow‑up
News Market Reaction – APYX
In the May 14 session, APYX gained 13.54%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Regulatory clearance | Positive | +6.8% | Expanded FDA 510(k) clearance adding power liposuction to AYON system. |
| May 07 | Earnings report | Positive | +21.9% | Q1 2026 revenue growth, narrowed losses, and raised full‑year guidance. |
| Apr 23 | Earnings date set | Neutral | -0.8% | Announcement of date and call details for upcoming Q1 2026 results. |
| Apr 01 | Product award | Positive | -1.6% | Renuvion winning 2026 NewBeauty award for minimally invasive skin tightening. |
| Mar 10 | Earnings report | Positive | +0.6% | Q4 and FY 2025 revenue growth, positive Q4 EBITDA, and 2026 outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows APYX often trading higher on fundamentally positive news (earnings beats, regulatory clearances), with only occasional divergence on softer, non-financial announcements.
Over the last six months, APYX has reported multiple milestones, including stronger Q4 2025 and Q1 2026 results, raised 2026 revenue guidance, and commercialization progress for the AYON Body Contouring System. Regulatory updates documented expanded AYON capabilities and improving margins with narrowing losses. A prior award for Renuvion produced a mild negative reaction, while earnings and clearance news generally saw positive follow‑through. Today’s retrospective clinical publication adds to the evidence base around Renuvion’s use alongside liposuction.
Key Terms
helium plasma radiofrequency medical
abdominoplasty medical
power-assisted liposuction medical
body-q medical
electrosurgical medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower abdominoplasty and revision rates, and comparable complication rates versus conventional liposuction alone
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open1. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).
The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates to power-assisted liposuction.
Key Findings from the 113‑Patient Study
- Patients treated with Renuvion reported statistically higher satisfaction with reduced appearance of excess skin (Body‑Q score 87.8 vs. 73.8; p=0.03)
- Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was also statistically higher (68.8 vs. 45.0; p=0.039)
- The rate of patients requiring abdominoplasty was more than
50% lower in the Renuvion group compared to the group receiving power-assisted liposuction only (30.0% vs.67.1% ) - Revision rates were significantly lower in the Renuvion group (
12.0% vs.37.5% ; p=0.038) - Complication rates remained similar between groups (
2.5% vs.2.7% )
“This study adds to the growing body of clinical evidence supporting the use of Renuvion in aesthetic body contouring,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical. “With more than 2 million liposuction procedures performed globally each year*, these statistically significant improvements in patient satisfaction and reduced revision rates underscore the value Renuvion provides to aesthetic surgeons and their patients.”
The retrospective study, led by Pablo D. Huber, MD, evaluated long-term (>12 month) Body-Q® patient-reported outcomes, procedural data, and safety profiles across 113 patients treated by a single surgeon. The Renuvion cohort (power-assisted liposuction + Renuvion) consistently reported higher satisfaction with skin quality and abdominal contour, with no increase in complications.
Apyx Medical’s latest technology, the AYON Body Contouring System™, builds on the proven foundation and technology of Renuvion, leveraging decades of clinical evidence and real-world experience to deliver precise, efficient, and effective energy-based solutions in an all-in-one system.
1A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open.
*Source: ISAPs 2024 Survey
About AYON Body Contouring System™:
AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
